There is a growing recognition that gliomas are complex tumors composed of neoplastic and non-neoplastic cells, which each individually contribute to cancer formation, progression and response to treatment. The majority of the non-neoplastic cells are tumor-associated macrophages (TAMs), either of peripheral origin or representing brain-intrinsic microglia, that create a supportive stroma for neoplastic cell expansion and invasion. TAMs are recruited to the glioma environment, have immune functions, and can release a wide array of growth factors and cytokines in response to those factors produced by cancer cells. In this manner, TAMs facilitate tumor proliferation, survival and migration. Through such iterative interactions, a unique tumor ecosystem is established, which offers new opportunities for therapeutic targeting.
r e v i e w Solid cancers develop in complex tissue environments that dramatically influence tumor growth, transformation and metastasis. In the microenvironment of most solid tumors are various non-neoplastic cell types, including fibroblasts, immune system cells and endothelial cells. Each of these stromal cell types produce growth and survival factors, chemokines, extracellular matrix constituents, and angiogenic molecules with the capacity to change the local milieu in which neoplastic cells grow and infiltrate. In the case of the most common brain tumor (glioma or astrocytoma), monocytes (macrophages and microglia) represent rich sources of these stromal factors. Moreover, the fact that as many as 30-50% of the cells in gliomas are microglia or macrophages [1] [2] [3] [4] raises the intriguing possibility that targeting microglia and macrophages might emerge as an adjuvant therapy for these difficult to manage cancers. In this review, we discuss the current understanding of these critical stromal elements in glioma.
Origins of glioma associated microglia and macrophages Microglia are the resident macrophages of the CNS. These mononuclear cells are distributed throughout the brain, where they function as key immune effector cells of the CNS. Originally discovered and characterized almost a century ago by Pio Del Rio Hortega 5 , the tissue origins of microglia and the mechanisms regulating their homeostasis in health and disease have been debated for many decades 6 . Contributing to the confusion was the use of particular experimental systems, including chimera mice generated by bone marrow (BM) transplantation of lethally irradiated recipients, and monocyte classification schemes reliant on the expression of specific cell surface antigens. Using bone-marrow transplantation, investigators concluded that, under homeostatic conditions, a considerable percentage of microglia are replaced by donor-derived monocytes 7 . Similar studies have also suggested that increases in microglia density in response to CNS damage involve both the expansion of endogenous resident microglia and the active recruitment of BM-derived microglial progenitors from the bloodstream [8] [9] [10] [11] [12] . Leveraging analogous methods, other reports demonstrated little or no contribution of circulating progenitors to the brain microglia pool. These studies argued that the expansion of microglia during microgliosis (microglial activation) results mainly from the local expansion of existing resident microglia 13 . These seemingly contradictory findings were finally resolved when chimeric animals generated by parabiosis were employed, which does not require either irradiation or transplantation. Using two models of acute and chronic microglia activation (axotomy and neurodegeneration), no microglial recruitment from the blood circulation was found 13 . In addition, acute peripheral recruitment of monocytes was observed in an experimental mouse model of autoimmune encephalitis (EAE); however, these infiltrating cells vanished following remission and did not contribute to the resident microglia pool 14 .
Notably, recent fate-mapping studies have identified immature yolk sac progenitors as the predominant source of brain microglia. Using sub-lethally irradiated C57BL/6 CD45.2+ newborns with hematopoietic cells isolated from CD45.1 + congenic mice, investigators found that, 3 months after transplantation, 95% of adult microglia remained of host origin. Second, they employed Cx3cr1 GFP/+ knock-in mice to demonstrate that myeloid cells expressing CD45 and the adult macrophage markers CD11b, F4/80 and CX3CR1 were detectable in the developing brain beginning at embryonic day 9.5 (E9.5). Third, in Csf1r-deficient mice, colony stimulating factor receptor (CSF1R) deficiency markedly reduced the development of microglia, whereas the circulating monocytes were unimpaired. Fourth, leveraging the Rosa26 R26R-eYFP/R26R-eYFP reporter strain intercrossed with mice in which the tamoxifen-inducible Cre ER recombinase gene was under the control of one of the endogenous runt-related transcription factor 1 (Runx1) locus promoters, the authors found that Runx1 + progenitors migrate from the yolk sac into the brain between E8.5 and E9.5, where they serve as the cells of origin for microglia 15 . Lastly, microglia derived from primitive c-kit + erythromyeloid precursors r e v i e w subsequently develop into CD45 + c-kit + CX3CR1 neg immature cells (A1), which then mature into CD45 + c-kit neg CX3CR1 + (A2) cells following CD31 downregulation and upregulation of F4/80 and CSF1R 16 . Together, these studies reveal that mouse myeloid progenitors from the blood do not substantially contribute to the pool of adult microglia after birth, establishing that the majority of adult microglia are yolk sac-derived and maintain themselves by virtue of longevity and limited self-renewal 13, 15, 17 . In this regard, resident microglia represent a distinct population of myeloid cells (Fig. 1) .
Whereas the naive CNS is occupied by resident microglia only, the diseased CNS presents a different picture. In many neuropathological conditions, the blood brain barrier is impaired, resulting in an infiltration of monocytes from the periphery. Understanding the differences between macrophages and microglia is critically important, as it is well-documented that they can react differently to various types of CNS insults. Recent studies using a complex parabiosis model with highly efficient permanent labeling of blood monocytes showed that peripheral mononuclear cells invade the inflamed CNS during EAE pathogenesis and have a primary role in disease progression 14 .
Monocytes originate from hematopoietic stem cells (HSCs) via progeny called macrophage-DC precursors. These cells differentiate in the bone marrow into monocytes, which are subsequently released into the blood circulation to colonize peripheral organs under both normal and inflammatory conditions 18 . Mouse monocytes can be further subdivided into two main populations: Ly6C + CX3CR1 int CCR2 + inflammatory monocytes and Ly6C − CX3CR1 hi CCR2 − circulating monocytes ( Fig. 1) 19, 20 . In the future, a clear distinction should be made between the contributions of microglia and blood monocyte to disease pathogenesis, further underscoring the need to better understand the fate and origins of blood monocytes.
Approaches to distinguishing microglia from invading monocytes have traditionally relied on the use of CD45 antibodies to separate resident microglia (CD45 low ) from macrophages of hematopoietic origin (CD45 high ) 21 . Analysis of human glioma samples by fluorescenceactivated cell sorting has revealed that the CD45 high population is larger than the CD45 low population, suggesting that gliomas contain more recruited monocytes than microglia 22 . This concept was recently challenged by a study using irradiation chimeras, which demonstrated that the majority of TAMs are intrinsic microglia and that these microglial cells upregulate their CD45 expression to constitute a significant proportion of the CD45 high monocyte population in gliomas 23 . In this study, the investigators protected the head from radiation to avoid a massive infiltration of monocytes as a result of a disrupted blood-brain barrier 23 . Another study using only single staining with either antibodies for CX3CR1 or CCR2 concluded that the majority of TAMs are mainly monocyte-derived macrophages (CCR2 + CX3C1 − ) and, to a smaller extent, resident microglia (CCR2 − CX3C1 + ) 24 . Although interesting, this study has several limitations, which include the lack of lineage tracing experiments to conclusively demonstrate that macrophages were derived from monocytes. Moreover, others have demonstrated that CX3CR1 is expressed by blood monocytes and that its expression is upregulated during monocyte differentiation into macrophages, implying that CX3CR1 does not represent a microglia-specific marker in either the naive brain 19, 20 or the context of glioma 25 (Fig. 2) . The discrepancies in the literature resulting from the use of bone-marrow chimeras and cell surface antibodies highlight the urgent need to re-evaluate these published conclusions and to perform lineage-tracing experiments using reporter mice that accurately distinguish microglia from monocytes and macrophages relative to their distinct roles in glioma formation, maintenance and progression (Fig. 2) .
TAMs and low-grade glioma Similar to their high-grade counterparts, the majority of World Health Organization (WHO) grade I and II astrocytomas contain microglia and macrophages 26 . Using CD68 and Iba1 antibodies, the percentage of monocytes in these low-grade tumors has been estimated at 15-30%, as compared with 10-15% in normal non-neoplastic brain specimens 2 . Depending on the region in which the tumor arises, the microglia fraction can be as high as 35-50%, as observed in WHO grade I pilocytic astrocytomas 1 . Notably, the percent of proliferating CD68 + cells may be higher in WHO grade I pilocytic astrocytomas (32%) relative to malignant WHO grade III-IV astrocytomas (8.6-13.4%) 27 . The importance of these immune system-like cells (macrophages and microglia) to glioma behavior is further underscored by two clinical observations: the number of CD68 + cells increases with increasing malignancy grade 28 and the recurrence-free survival of patients with pilocytic astrocytoma is inversely related to the percentage of CD68 + cells in the tumor 29 .
To gain insights into the contributions of microglia to low-grade glioma biology, we previously leveraged a murine model of neurofibromatosis type 1 (NF1) optic glioma. 15-20% of children with In adult life, monocytes are generated from HSCs that differentiate into granulocytemacrophage progenitors (GMPs) and then into monocyte-dendritic cell progenitors (MDPs). Mature Ly6C hi CCR2 + CX3CR1 low/int inflammatory monocytes are released into circulation 20 , where they can migrate to tissues in response to specific pathological conditions. These cells can also give a rise to circulating monocytes. Microglia originate from yolk sac progenitors in the neuroepithelium beginning around E8.5 in the mouse. In the adult brain, they express high levels of CX3CR1, CD11b and F4/80, but low levels of CD45 and no CCR2.
Reprinted with permission, Cleveland Clinic Center for Medical Art & Photography © 2015.
All rights reserved.
npg r e v i e w the NF1 inherited cancer predisposition syndrome develop pilocytic astrocytomas involving the optic pathway 30 . These children are born with a germline NF1 gene mutation (NF1 +/− ) and develop brain tumors following somatic NF1 gene inactivation in cells of the astroglial lineage 1 . Similarly, Nf1 +/− mice with somatic Nf1 gene inactivation in neuroglial progenitors develop low-grade glial neoplasms involving the optic nerve and chiasm 31 . As observed in their human counterparts, these murine low-grade tumors are infiltrated by TAMs 32 . The majority of the TAMs in Nf1 mouse optic gliomas are CD11b high CD45 low , and therefore most likely microglia 33 , which are evident early during tumorigenesis 34 . The role of these stromal cells in mediating glioma growth has been revealed by preclinical studies in which pharmacologic (minocycline, c-Jun-NH(2)-kinase inhibition) or genetic (gangciclovir treatment of CD11b − thymidine kinase-expressing mouse line) silencing of microglial function results in reduced tumor proliferation 2, 35, 36 . Moreover, Nf1 optic glioma mice with reduced expression of a chemokine receptor responsible for directional macrophage migration (CX3CR1) demonstrate delayed tumor formation 33 . Collectively, these data establish critical functions for microglia in murine low-grade glioma formation and maintenance. Notably, similar requirements for monocytes in another low-grade glial (Schwann) cell tumor have been reported. In these studies, mast cells and macrophages are the stromal cell types essential for neurofibroma development and continued growth 37, 38 . Although the mechanisms underlying microglia stimulation of low grade glioma growth have not been fully elucidated, Nf1 +/− TAMs produce paracrine factors and chemokines capable of increasing Nf1-deficient astroglial cell proliferation 35 . One such chemokine, stroma-derived factor-1 (SDF-1 or CXCL12), is increased in Nf1 +/− TAM relative to wild-type (normal) microglia 39, 40 . SDF-1 operating through the CXCR4 receptor promotes optic glioma cell survival, such that CXCR4 inhibition reduces tumor growth in vivo. A more complete characterization of TAMs support of tumor maintenance has been performed using optimized RNA-sequencing methods 41, 42 .
TAMs and high-grade (malignant) glioma TAM activation. Macrophages and microglia are mononuclear cell types characterized by considerable diversity and plasticity. As such, different types of macrophage activation have been defined following in vitro stimulation. The pro-inflammatory M1 phenotype is typically acquired after stimulation with Toll-like receptor 4 (TLR4) ligands and IFN-γ, while the alternative M2 phenotype occurs after IL-4, IL-10 and IL-13 exposure 43 . Alternative macrophage activation can be further subdivided into M2a (Th2 responses, type II inflammation, killing of pathogens, allergy), M2b (Th2 activation, immunoregulation) and M2c (immunoregulation, matrix deposition, tissue remodeling) activation states 43, 44 . These polarized subpopulations of macrophages differ with respect to receptor expression, effector function, and cytokine and chemokine production 45 . Given that the definitions of these mutually exclusive activation states are based on in vitro conditions, they do not translate well to the in vivo setting.
Several studies have analyzed the expression of polarization marker genes in TAMs either in vitro or in vivo [46] [47] [48] . Similar to solid tumors arising in other organs, TAMs exhibit alternative macrophage activation, including increased production of anti-inflammatory molecules (for example, transforming growth factor β (TGF-β) ARG1 and IL-10) as well as those that support tissue remodeling and angiogenesis (for example, VEGF, MMP2, MMP9 and MT1-MMP). In addition, TAMs also produce pro-inflammatory molecules (for example, TNF-α, IL1-β and CXCL10) 46, [48] [49] [50] [51] [52] .
Using RNA microarray analyses, the expression profiles of glioma-associated microglia and macrophages, and control microglia were compared with those from control animals obtained by CD11b antibody-mediated magnetic-activated cell sorting. Approximately 1,000 transcripts were differentially expressed by twofold or more in glioma-associated microglia and macrophages relative to control microglial cells. This expression pattern had only partial overlap with reported gene signatures for M1-, M2a-, M2b-and M2c-polarized macrophages (Fig. 3) 53 .
Similarly, other investigators have performed correlative analyses to determine whether the survival of patients with high-grade gliomas is associated with the expression of either M1 or M2 polarizationspecific markers. One such M1 polarization marker, CD74, was found to be expressed by human TAMs and was positively correlated with increased patient survival 54 . In another study, F11R was established as a monocyte prognostic marker for glioblastoma, where it negatively correlates with patient survival and may be critical for defining a subpopulation of stromal cells for future potential therapeutic intervention 55 .
Based on the current literature, it is clear that the current M1 and M2 classification schemes are not absolute, but constitute relative definitions when studying TAMs in vivo. In this regard, TAMs express markers that are characteristic of either the M1 or M2 phenotype. As such, glioma-derived M-CSF induces a shift of microglia and macrophages toward the M2 phenotype, which increases tumor growth 56 . Similarly, mTOR 57 or CSF-1 (ref. 56 ) inhibition shifts to the M1 phenotype. Similar anti-tumor effects have been shown by dopamine or targeting miR-142-3p, which affects the M2-polarization of TAMs 58, 59 . On the basis of these studies, the identification of targeting approaches that convert M2 macrophages to M1 macrophages has been suggested as a potential therapeutic strategy to reduce glioma growth. However, other studies have suggested that M1 specific markers or associated pathways positively correlate with glioma growth. For example, IL1-β was shown to promote glioma growth 25 . Considering the plasticity and the fact that the M1 and M2 phenotype is a classification scheme defined in cultured macrophages, There are many factors that mediate microglia chemoattraction, including chemokines, ligands of complement receptors, neurotransmitters and ATP. It is presently unclear whether there exist distinct factors that recruit intrinsic (resident) microglia or peripheral macrophages to the tumor. The first chemoattractant factor identified was monocyte chemoattractant protein-1 (MCP-1), also known as CCL2. Ectopic expression of CCL2 in rat glioma cells resulted in a tenfold higher density of Ox42-positive cells in vivo and the tumors generated with CCL2-expressing glioma cells were more than threefold larger in size, resulting in reduced rat survival 60 . The importance of MCP-1 to human glioma biology has recently been challenged, with a stronger correlation being observed between MCP-3, rather than MCP-1, expression and the density of infiltrating microglia and macrophages 61 . Hepatocyte growth factor and scatter factor released by glioma cells similarly function as chemoattractants for microglia, but this has only been shown using a microglial cell line 62 . CXCL12 (SDF-1) is another potent microglia and macrophage recruiting molecule, especially for attracting TAMs to hypoxic areas 63 . In the normal brain, the receptor for the cytokine CX3CL1 (fractalkine), CX3CR1, is mostly expressed by microglial cells, where it has been established as a reliable marker for in vivo microglia imaging. The CX3CL1 and CX3CR1 signaling cascade is important for neuron-microglia communication, such that deletion of CX3CR1 impairs synapse plasticity during development 64 . However, conflicting data exist regarding the importance of CX3CL1 in tumor-directed TAM migration 25, 65, 66 .
The growth factor glial cell-derived neurotrophic factor (GDNF) was initially identified as a released factor from the glial cell line B49, and was found to promote the survival and differentiation of dopaminergic neurons. Mouse and human gliomas also secrete GDNF, which serves as a strong chemoattractant for microglia. When glioma cells were encapsulated in hollow fibers to allow for the passage of molecules, but not cells, microglia accumulated around these fibers following brain implantation. GDNF mediated this attraction, as revealed by GDNF knockdown in the encapsulated glioma or by overexpression of GDNF in an encapsulated fibroblast cell line. Notably, the upregulation of GFAP in astrocytes around hollow fibers was not affected by GDNF knockdown, indicating that GDNF largely acts on microglia 67 .
Lastly, CSF-1 is released by glioma cells, where it can also function as a microglia chemoattractant. Treatment of mice with a blood-brain barrier-permeable CSF-1R antagonist reduces the density of TAMs and attenuated glioblastoma invasion in vivo 68 . In addition, granulocytemacrophage colony-stimulating factor (GM-CSF) can serve as a chemoattractant for microglia, as GM-CSF knockdown reduces microglia-dependent invasion in organotypic brain slices as well as attenuated the growth of intracranial gliomas in vivo 69 . In conclusion, there are many factors that can attract TAMs to the glioma (Fig. 4) . TAM regulation of glioma growth and migration. The accumulation of TAMs in and around glioma has raised the question as to whether these mononuclear cells are bystanders or whether they actively influence glioma growth and invasion. Accumulating evidence indicates that TAMs promote glioma growth and invasion. One study noted that, in the presence of microglial cells, the motility of the murine glioma cells was increased threefold in vitro 70 . In contrast, oligodendrocytes and endothelial cells only weakly promote glioma motility 70 . In situ, glioma growth can be monitored using organotypic brain slices. These slices can be depleted of microglia using liposomes filled with the toxin clodronate, resulting in reduced glioma invasion and growth 71 . A complementary in vivo approach entails the use of transgenic mice expressing the herpes simplex virus thymidine kinase gene under the control of the Cd11b promoter. In the CNS, CD11b is specifically expressed by microglia. When ganciclovir is infused into the brain, there is a marked reduction in microglia number, which concomitantly results in attenuated glioma growth in vivo 50 .
Several factors released from microglia have been reported to promote glioma proliferation and/or migration. Microglia synthesize and release stress-inducible protein 1 (STI1), a cellular prion protein ligand that increases the proliferation and migration of glioblastomas in vitro and in vivo 72 . In addition, microglia release epidermal growth factor (EGF), which also stimulates glioblastoma cell invasion 68 . This glioma-promoting activity by microglia is triggered by CSF-1, which is constitutively released by the tumor cells. As described above, CSF-1 is a chemoattractant for microglia and, at the same time, converts microglia into a pro-tumorigenic phenotype 56 . CCL2 is another factor released from human glioma cell lines and acts on the CCL2 receptor (CCR2) expressed on microglia 73 . CCL2 can trigger the release of IL-6 from microglia, which in turn, promotes the invasiveness of glioma cells 74 . It should be noted that there may be species differences, npg r e v i e w as it was recently described that mouse microglia do not express CCR2 (ref. 75 ).
Transforming growth factor-β (TGF-β) also increases the migration of glioma cells through processes that likely involve increased integrin expression and function 76 . TGF-β is predominantly released from microglia when studied in co-culture systems, such that blocking TGF-β signaling impairs glioma growth 77 . In addition, TGF-β2 induces the expression of matrix metalloprotease-2 (MMP2) and suppresses the expression of tissue inhibitor of metalloproteinases (TIMP)-2, which degrades the extracellular matrix to promote glioma invasion 76 . Although antagonizing TGF-β function was initially considered as a potential anti-tumor therapy, it has severe side effects, as systemic inhibition or lack of TGF-β signaling results in acute inflammation and disruption of immune system homeostasis 77 .
MMP2 enzyme is released in a pro-form that needs to be cleaved to become active. The prominent enzyme for pro-MMP2 cleavage is the membrane-bound metalloprotease MT1-MMP. Under normal conditions, microglia do not elaborate MT1-MMP (membrane type 1-matrix metalloproteinase), but, when exposed to glioma cells, they do upregulate MT1-MMP expression. Microglial MT1-MMP expression then increases glioma growth in organotypic slices. In this regard, slices obtained from MT1-MMP-deficient mice harbor substantially smaller tumors. Moreover, when microglia are depleted from MT1-MMPdeficient organotypic slices, glioma growth is further reduced, indicating that MT1-MMP is not the only glioma-promoting factor expressed by microglia. In human glioma samples, MT1-MMP expression positively correlates with the increasing glioma malignancy grade 50 .
The involvement of the TLR signaling cascade in glioma-microglia interactions was initially inferred by the observation that deletion of MyD88, an adaptor protein of most Toll-like receptors, inhibits MT1-MMP induction in microglia. Toll-like receptors are prominent detectors of DNA fragments or bacterial cell wall components, and are important for mediating immunologic responses to pathogens 78 . In microglia, TLR2 was identified as the major TLR involved in triggering MT1-MMP upregulation. In this manner, gliomas implanted into Tlr2-deficient mice are substantially smaller, and the survival of these mice is prolonged. TLR2 forms heterodimers with TLR1 and TLR6, which is important for modulating MT1-MMP expression; deletion of both TLR1 and TLR6 results in reduced MT1-MMP expression. In addition, treatment with TLR2-neutralizing antibodies reduces glioma-induced microglial MT1-MMP expression and attenuates glioma growth 79 .
In a screen for endogenous ligands released from glioma cells, versican was identified as a candidate molecule for triggering TLR2 signaling 80 . Versican exists as different splice variants, V0, V1 and V2. The V0 and V1 isoforms are highly expressed in mouse and human gliomas, and reduced glioma versican expression is associated with decreased microglial MT1-MMP expression in vitro and in vivo. Furthermore, inoculation of versican-silenced gliomas results in smaller tumors and longer survival rates relative to controls. Notably, the effect of versican signaling on glioma growth depends on the presence of microglia. The ability of glioma-produced versican to trigger increased TLR2 expression converts microglia into a pro-tumorigenic phenotype characterized by the upregulation of MT1-MMP and MMP9 expression. This feed-forward loop establishes an interdependent circuit of cellular interactions that increases glioma growth and invasion 81 .
TAMs not only target glioma cells, but also affect angiogenesis to indirectly affect tumor growth. Signaling through the receptor for advanced glycation end product (RAGE) is important for the process. RAGE ablation abrogates angiogenesis, which can be reconstituted with wild-type microglia or macrophages. This TAM activity correlates with the expression of VEGF, an important pro-angiogenic factor 82 (Fig. 5) .
The effects of microglia and macrophages on glioma stem cells Glioblastomas contain a subpopulation of cells with stem cell-like properties (self-renewal, multi-lineage differentiation) capable of reconstituting the native tumor following implantation into naive hosts. These glioma stem cells (GSCs) reside in the perivascular niche, where they can be highly resistant to radiation and chemotherapy [83] [84] [85] (Fig. 6) . The importance of GSCs to microglia attraction is also underscored by a positive correlation between the density of GSCs and TAMs, indicating that GSCs may recruit TAMs more efficiently than their more differentiated neoplastic counterparts 86 . A recent study showed that GSCs release periostin, which accumulates in the perivascular niche. Periostin acts as a chemoattractant for TAMs, which is mediated by signaling through the integrin receptor α v β 3 24) . TAMs also influence the properties of GSCs, in that TGF-β released from TAMs induce MMP-9 expression and increase GSC invasiveness 52 . In addition, naive microglia can reduce the sphereforming ability of human stem cells to suppress glioma growth, whereas microglia or monocytes cultured from glioma patients lack this anti-tumorigenic potential 87 . Supernatants from glioma stem cells likewise inhibit the phagocytosis activity of TAMs and induce the secretion of interleukin-10 and TGF-β 88 .
Microglia and macrophages as targets for glioma therapy For several decades, our understanding of glioma biology has largely been driven by studies focused on the genetic and molecular changes that occur in the cancer cells and their contributions to deregulated cell growth. Over the past several years, work from numerous laboratories, including our own groups, has revealed that glioma growth is dependent on growth regulatory signals that emanate from the tumor microenvironment. In this regard, it is important to recognize that brain tumors are complex microcosms in which the communication between neoplastic and non-neoplastic cells will influence not only gliomagenesis 89 , but may also modify glioma responses to standard therapy. The identification of these glioma microenvironment-derived signals represents an initial step toward developing stroma-directed glioma therapies, with the ultimate goal of combining these therapies with anti-neoplastic cell-targeted therapies.
In this regard, the induction of HIF-1 following glioma radiation results in the recruitment of bone marrow-derived myeloid cells, partially due to the activation of stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4. As such, activation of SDF-1 and CXCR4 promotes vasculogenesis and tumor recurrence. These findings support the notion that better outcomes for glioblastoma might be achieved using a combination of radiotherapy and the clinically approved small molecule inhibitor of CXCR4 signaling, AMD3100 (ref. 90 ). These observations are further supported by a different glioma model, which showed that tumor-secreted SDF-1 is one important factor in radiotherapy-induced tumor invasiveness, where it exerts its primary effect through macrophage mobilization and tumor revascularization 91 . Similar observations were made when human recurrent glioblastomas were treated with anti-angiogenic therapy. The increased TAM number correlated with poor survival, suggesting that TAMs may participate in the escape from anti-angiogenic therapy, and therefore represent a potential biomarker of resistance as well as a logical therapeutic target for recurrent glioblastoma treatment 92 . In support of these human correlative data, murine glioma studies revealed that glioblastoma resistance to anti-VEGF therapy is associated with increased myeloid cell infiltration 93 .
Interfering with CSF-1 signaling is another potential approach to targeting TAM regulation of glioma growth. One study used an inhibitor of the CSF-1 receptor in a mouse proneural glioblastoma model to increase survival and shrink established tumors 56 . Periostin has also emerged as an interesting target for attenuating the tumor-supportive phenotype of TAMs by interrupting integrin αvβ 3 signaling 24 .
Interfering with this pathway with a blocking peptide impairs TAM recruitment. Moreover, it may be possible to exploit the interaction of TAMs with glioma initiating cells. Using this strategy, in a drug screen, Amphotericin B was identified as a molecule that enhanced the microglial effect on brain tumor initiating cell (BTIC) cycle growth arrest and differentiation 87 , whereas Stat3 inhibition has been shown to activate TAMs and inhibit glioma growth in mice 94 .
Minocycline, an antibiotic, interferes with the process of microglia activation. A rat model of glioma revealed synergistic activity when systemic BCNU (chemotherapy) treatment was combined with the local delivery of minocycline to impair microglia activation 95 . Currently, investigators at the University of Utah are recruiting patients for a phase I clinical trial using minocycline as adjuvant therapy (clinicaltrials.gov, #NCT02272270, https:// clinicaltrials.gov/ct2/show/NCT02272270?term=NCT02272270&r ank=1). In addition, immunotherapy using activated natural killer (NK) cells combined with the antibody mAb9.2.27 directed against the proteoglycan Neuroglial-2 (NG2) has shown beneficial effects, which are partly a result of a reversal of the tumorpromoting effects of TAMs 96 . Collectively, these studies suggest that TAMs modify the glioma response to standard and anti-angiogenic therapy.
Conclusions
It is now evident that TAMs home to the evolving glioma and interact in a complex fashion with the tumor environment to promote glioma growth in mouse models and in human patients (Fig. 6) . However, there are still many unanswered questions. It is not clear what factors are truly responsible for mediating the interaction between glioma cells and microglia and macrophages. In this respect, we do not know how microglia and macrophages interact in the tumor, and whether they acquire distinct properties and execute distinct functions. It remains also an open question as to whether TAMs acquire different functional phenotypes depending on individual glioma types (low-grade versus high-grade, glioblastoma molecular subtypes). Similarly, even in a given tumor, TAMs might interact differently with different neoplastic cell types (GSCs, differentiated astrocytoma cells). Nonetheless, after decades of applying treatments directed against the tumor cells directly, TAMs have emerged as exciting targets for therapeutic intervention. Further investigation into the mechanisms and interactions between TAM populations and the variety of neoplastic and non-neoplastic cells in these tumors may one day yield new glioma treatment strategies. 
